Business
President and CEO of Medicenna Therapeutics Corp., Dr. Fahar Merchant, is Featured on The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - January 21, 2020) - The Stock Day Podcast welcomed Medicen...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"President and CEO of Medicenna Therapeutics Corp., Dr. Fahar Merchant, is Featured on The Stock Day PodcastPhoenix, Arizona--(Newsfile Corp. - January 21, 2020) - The Stock Day Podcast welcomed Medicenna Therapeutics Corp. (TSX: MDNA) (OTCQB: MDNAF) (\"the Company\"), a clinical stage immunotherapy company focused on oncology and the development and commercialization of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines™ (ECs) for the treatment of a broad range of cancers. CEO and President of the Company, Dr. Fahar Merchant, joined Stock Day host Everett Jolly. Dr. Merchant began the interview by providing background information about the Company. \"Medicenna is very focused in the oncology space. We are developing a really exciting, new kind of therapy around interleukins,\" explained Dr. Merchant. \"These are very special molecules that target tumors and are also able to stimulate the immune system,\" said Dr. Merchant. \"We've got a program that has just completed a Phase 2b clinical trial for recurrent glioblastoma,\" he added, noting that this condition represents the most aggressive form of brain cancer with very few treatment options available. This is the same brain cancer that claimed the life of Senator John McCain.Jolly then asked about the details of the MDNA55 clinical trial. \"The patients that we treated in this clinical trial were patients that had already been through surgery, radiation, and chemotherapy - they had essentially failed these three therapies and the tumor came back,\" explained Dr. Merchant. \"The therapies that are currently available at recurrence will extend the survival of these patients to perhaps 6 to 8 months post-treatment,\" continued Dr. Merchant. \"For the first time we are able to show that with a single treatment of MDNA55 the median survival in the patients treated was extended to 15 months,\" shared Dr. Merchant. \"We're doubling the survival in this patient population, which is something that has not happened in the past two decades.\"\"What are the next steps for MDNA55?\" asked Jolly. \"We have data now in 118 patients so far,\" said Dr. Merchant. \"The drug has already received orphan drug designation from the FDA and the European regulators as well,\" he explained. \"The drug has also been granted fast-track designa...